These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 14585357

  • 1. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes.
    Drayton S, Rowe J, Jones R, Vatcheva R, Cuthbert-Heavens D, Marshall J, Fried M, Peters G.
    Cancer Cell; 2003 Oct; 4(4):301-10. PubMed ID: 14585357
    [Abstract] [Full Text] [Related]

  • 2. Stepwise neoplastic transformation of a telomerase immortalized fibroblast cell line.
    Zongaro S, de Stanchina E, Colombo T, D'Incalci M, Giulotto E, Mondello C.
    Cancer Res; 2005 Dec 15; 65(24):11411-8. PubMed ID: 16357149
    [Abstract] [Full Text] [Related]

  • 3. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.
    Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G.
    EMBO J; 2002 Jun 17; 21(12):2936-45. PubMed ID: 12065407
    [Abstract] [Full Text] [Related]

  • 4. The significance of p16INK4a in cell defenses against transformation.
    Drayton S, Brookes S, Rowe J, Peters G.
    Cell Cycle; 2004 May 17; 3(5):611-5. PubMed ID: 15044857
    [Abstract] [Full Text] [Related]

  • 5. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype.
    Milyavsky M, Shats I, Erez N, Tang X, Senderovich S, Meerson A, Tabach Y, Goldfinger N, Ginsberg D, Harris CC, Rotter V.
    Cancer Res; 2003 Nov 01; 63(21):7147-57. PubMed ID: 14612508
    [Abstract] [Full Text] [Related]

  • 6. The tumor-suppressive functions of the human INK4A locus.
    Voorhoeve PM, Agami R.
    Cancer Cell; 2003 Oct 01; 4(4):311-9. PubMed ID: 14585358
    [Abstract] [Full Text] [Related]

  • 7. Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts.
    Huot TJ, Rowe J, Harland M, Drayton S, Brookes S, Gooptu C, Purkis P, Fried M, Bataille V, Hara E, Newton-Bishop J, Peters G.
    Mol Cell Biol; 2002 Dec 01; 22(23):8135-43. PubMed ID: 12417717
    [Abstract] [Full Text] [Related]

  • 8. Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors.
    Horiguchi M, Koyanagi S, Okamoto A, Suzuki SO, Matsunaga N, Ohdo S.
    Cancer Res; 2012 Jan 15; 72(2):395-401. PubMed ID: 22102693
    [Abstract] [Full Text] [Related]

  • 9. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE, Ramsey MR, Balasubramanian P, Castrillon DH, DePinho RA.
    Oncogene; 2004 Jan 15; 23(2):379-85. PubMed ID: 14724566
    [Abstract] [Full Text] [Related]

  • 10. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M, Wu K, Fu M, Rao M, Albanese C, Russell RG, Lian H, Bregman D, White MA, Pestell RG.
    Cancer Res; 2004 Jun 15; 64(12):4122-30. PubMed ID: 15205322
    [Abstract] [Full Text] [Related]

  • 11. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.
    Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L.
    Oncogene; 2003 Aug 07; 22(32):5055-9. PubMed ID: 12902988
    [Abstract] [Full Text] [Related]

  • 12. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest.
    Rowland BD, Denissov SG, Douma S, Stunnenberg HG, Bernards R, Peeper DS.
    Cancer Cell; 2002 Jul 07; 2(1):55-65. PubMed ID: 12150825
    [Abstract] [Full Text] [Related]

  • 13. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence.
    Zou X, Ray D, Aziyu A, Christov K, Boiko AD, Gudkov AV, Kiyokawa H.
    Genes Dev; 2002 Nov 15; 16(22):2923-34. PubMed ID: 12435633
    [Abstract] [Full Text] [Related]

  • 14. Transformation of human and murine fibroblasts without viral oncoproteins.
    Boehm JS, Hession MT, Bulmer SE, Hahn WC.
    Mol Cell Biol; 2005 Aug 15; 25(15):6464-74. PubMed ID: 16024784
    [Abstract] [Full Text] [Related]

  • 15. Unraveling human tumor suppressor pathways: a tale of the INK4A locus.
    Voorhoeve PM, Agami R.
    Cell Cycle; 2004 May 15; 3(5):616-20. PubMed ID: 15044859
    [Abstract] [Full Text] [Related]

  • 16. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence.
    Peeper DS, Shvarts A, Brummelkamp T, Douma S, Koh EY, Daley GQ, Bernards R.
    Nat Cell Biol; 2002 Feb 15; 4(2):148-53. PubMed ID: 11812999
    [Abstract] [Full Text] [Related]

  • 17. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
    Simon M, Park TW, Köster G, Mahlberg R, Hackenbroch M, Boström J, Löning T, Schramm J.
    J Neurooncol; 2001 Dec 15; 55(3):149-58. PubMed ID: 11859969
    [Abstract] [Full Text] [Related]

  • 18. Dual inactivation of RB and p53 pathways in RAS-induced melanomas.
    Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L.
    Mol Cell Biol; 2001 Mar 15; 21(6):2144-53. PubMed ID: 11238948
    [Abstract] [Full Text] [Related]

  • 19. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
    Obata M, Imamura E, Yoshida Y, Goto J, Kishibe K, Yasuda A, Ogawa K.
    Mol Carcinog; 2001 Sep 15; 32(1):9-18. PubMed ID: 11568971
    [Abstract] [Full Text] [Related]

  • 20. G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
    Ausserlechner MJ, Obexer P, Geley S, Kofler R.
    Leukemia; 2005 Jun 15; 19(6):1051-7. PubMed ID: 15800668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.